Edition:
United Kingdom

Kalvista Pharmaceuticals Inc (KALV.OQ)

KALV.OQ on NASDAQ Stock Exchange Global Market

15.91USD
22 Aug 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$15.91
Open
$16.77
Day's High
$16.77
Day's Low
$15.83
Volume
22,131
Avg. Vol
51,439
52-wk High
$34.65
52-wk Low
$14.61

Latest Key Developments (Source: Significant Developments)

Kalvista Pharmaceuticals Promotes Ben Palleiko To Chief Business Officer In Addition To Current Role As CFO
Wednesday, 27 Mar 2019 

March 27 (Reuters) - Kalvista Pharmaceuticals Inc ::KALVISTA PHARMACEUTICALS ANNOUNCES THE PROMOTION OF BENJAMIN L. PALLEIKO TO INCLUDE CHIEF BUSINESS OFFICER.KALVISTA PHARMACEUTICALS - PROMOTION OF BEN PALLEIKO TO CHIEF BUSINESS OFFICER IN ADDITION TO CURRENT ROLE AS CFO, EFFECTIVE IMMEDIATELY.  Full Article

Kalvista Pharmaceuticals Qtrly Net Loss $0.06
Tuesday, 31 Jul 2018 

July 31 (Reuters) - Kalvista Pharmaceuticals Inc ::KALVISTA PHARMACEUTICALS PROVIDES OPERATIONAL UPDATE AND FISCAL YEAR FINANCIAL RESULTS.Q4 REVENUE $4.8 MILLION VERSUS $100,000.QTRLY NET LOSS $0.06.  Full Article

Kalvista Pharmaceuticals Q3 Loss Per Share $0.49
Friday, 16 Mar 2018 

March 16 (Reuters) - Kalvista Pharmaceuticals Inc ::KALVISTA PHARMACEUTICALS REPORTS FISCAL THIRD QUARTER RESULTS.Q3 LOSS PER SHARE $0.49.Q3 REVENUE $2.3 MILLION VERSUS $200,000.‍CASH AND CASH EQUIVALENTS WERE $58.7 MILLION AS OF JANUARY 31, 2018​.  Full Article

Kalvista Pharmaceuticals Commences Two Clinical Trials
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Kalvista Pharmaceuticals Inc ::KALVISTA PHARMACEUTICALS COMMENCES TWO CLINICAL TRIALS.KALVISTA PHARMACEUTICALS INC - TOP-LINE RESULTS ARE EXPECTED IN SECOND HALF OF 2019 FOR KVD001.KALVISTA PHARMACEUTICALS INC - EXPECTS TO PROVIDE AN UPDATE ON STATUS AND PROGRESS OF HAE PORTFOLIO, INCLUDING KVD900, IN MID-2018.  Full Article

Kalvista Pharmaceuticals Reports Q2 Loss Per Share $0.50
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Kalvista Pharmaceuticals Inc ::KALVISTA PHARMACEUTICALS REPORTS FISCAL SECOND QUARTER RESULTS.Q2 LOSS PER SHARE $0.50.Q2 REVENUE $1.1 MILLION VERSUS $200,000.  Full Article

Longwood Fund II reports 8.7 pct stake in Kalvista Pharmaceuticals ‍​
Friday, 20 Oct 2017 

Oct 20 (Reuters) - Kalvista Pharmaceuticals Inc :Longwood Fund II Lp reports 8.7 pct stake in Kalvista Pharmaceuticals Inc as of Oct 12 - sec filing‍​.  Full Article

Kalvista Pharmaceuticals announces collaboration with Merck
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Kalvista Pharmaceuticals Inc :Kalvista Pharmaceuticals announces collaboration with Merck.Kalvista Pharmaceuticals - ‍investigational intravitreal DME candidate KVD001 phase 2 clinical trial still planned to initiate in 2017​.Kalvista Pharmaceuticals Inc - ‍Merck acquires 9.9% stake in Kalvista in private placement​.Kalvista Pharmaceuticals Inc - deal includes ‍$37 million upfront fee plus potential milestone payments and sales royalties​.Kalvista Pharmaceuticals Inc - ‍Kalvista also has granted to Merck a similar option to acquire investigational orally delivered molecules for DME​.Kalvista - ‍under deal terms, co granted to Merck rights including an option to acquire KVD001 through a period following completion of phase 2 trial.Kalvista - Co will fund, retain control over planned phase 2 clinical trial of KVD001, development of investigational oral DME compounds through phase 2​.Kalvista - eligible to get payments associated with exercise of options by Merck, achievement of milestones for each program potentially total $715 million​.  Full Article

KalVista Pharmaceuticals reports Q1 loss per share of $0.51
Thursday, 14 Sep 2017 

Sept 14 (Reuters) - Kalvista Pharmaceuticals Inc :KalVista pharmaceuticals reports fiscal first quarter results.Q1 loss per share $0.51.Q1 revenue $100,000 versus $1.0 million.KalVista Pharmaceuticals Inc - ‍Intravitreal Diabetic Macular Edema Candidate KVD001 remains on track for Phase 2 in 2017​.KalVista Pharmaceuticals Inc - ‍cash and cash equivalents were $26.5 million as of July 31, 2017​.  Full Article